CardieX (ASX:CDX) 3-Year Revenue Growth Rate : -15.50% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is CardieX 3-Year Revenue Growth Rate?

CardieX's Revenue per Share for the six months ended in Dec. 2023 was A$0.07.

During the past 12 months, CardieX's average Revenue per Share Growth Rate was 218.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was -15.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was -22.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was -26.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of CardieX was 41.80% per year. The lowest was -38.80% per year. And the median was -15.50% per year.

Competitive Comparison of CardieX's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, CardieX's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CardieX's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CardieX's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where CardieX's 3-Year Revenue Growth Rate falls into.

CardieX 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

CardieX (ASX:CDX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

CardieX 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of CardieX's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CardieX (ASX:CDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CardieX Ltd (ASX:CDX) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

55 Lime Street, Suite 301, Level 3, Sydney, NSW, AUS, 2000

Website

https://www.cardiex.com

CardieX Ltd is a global health technology company, developing solutions for health disorders. The AtCor Medical division develops medical devices for measuring arterial stiffness and central blood pressure waveforms based on its patented SphygmoCor technology. It also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. It reports in a single segment being sales of cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company has three reportable segments by geographic area namely the Americas includes, global pharmaceutical trials business, Europe includes, the Middle East and Africa and the Asia Pacific includes, Asia and Australia/New Zealand.

CardieX (ASX:CDX) Headlines

No Headlines